ACCP Virtual Poster Symposium (May 22-24, 2012): Scientific Poster Symposium Session 1 -- Original Research

1E

Post hoc analysis of pooled safety data from eleven Phase 3 clinical trials to identify potential pharmacodynamic drug interactions between tapentadol and SSRIs/SNRIs

Vincent Brett, MS, PharmD, Christopher Sikes, PharmD, Jim Xiang, PhD, Charles Oh, MD and David Biondi, DO
Janssen Scientific Affairs, LLC, Raritan, NJ

PDF file

21

Acute pancreatitis associated with GLP-1 Agonists (Exenatide and Liraglutide) exposure: a meta-analysis of published randomized controlled clinical trials

Carlos Alves, Pharm.D.¹ and Francisco Batel-Marques, Pharm.D., PhD²
1School of Pharmacy, University of Coimbra, Coimbra, Portugal
2Health Techonology Assessment (HTA) Centre - AIBILI, Coimbra, Portugal

PDF file

23

Novel Method to Maximize Levofloxacin Pharmacodynamics for the Treatment of Systemic Gram Negative Infections Based on the Population Distribution of Patient Demographics at a Community Hospital

Andras Farkas, PharmD and Catherine Hoffman, MT, ASCP
Nyack Hospital, Nyack, NY

PDF file

25

Comparison of the relative oral bioavailability of tolvaptan administered via nasogastric tube to tolvaptan tablets swallowed intact

Elizabeth B. McNeely, PharmD¹, J. Heyward Hull, PharmD, MS¹, Kirkwood F. Adams Jr., MD², Jasmine Talameh, PharmD¹, Brian Simmons, PharmD, MSCR¹, Jill Henry, PharmD¹, Kim L. R. Brouwer, PharmD, PhD¹ and J. Herbert Patterson, PharmD, FCCP³
1University of North Carolina, Eshelman School of Pharmacy, Chapel Hill, NC
2University of North Carolina, School of Medicine, Chapel Hill, NC
3University of North Carolina, Eshelman School of Pharmacy and School of Medicine, Chapel Hill, NC

PDF file

26

Development of a Pharmacokinetic Model for Oseltamivir in Ferrets Using Iterative Two-Stage Analysis

Kuo-Hsiung Yang, Pharm.D, M.S.¹, Micaela Reddy, Ph.D², Chandra Pamulapati, Ph.D², Craig R. Rayner, Pharm.D² and Alan Forrest, Pharm.D³
1SUNY Buffalo (Buffalo, NY), Hoffmann-La Roche (Nutley, NJ), Rutgers University (Piscataway, NJ), .
2Hoffmann La-Roche (Nutley, NJ), Nutley, NJ
3SUNY-Buffalo School of Pharmacy, Buffalo, NY

PDF file

27

Application of pharmacokinetic and pharmacodynamic analysis to support the selection of a 40 mg dose for the immediate-release omeprazole formulation in PA32540

Laurene Wang-Smith, PhD¹ and John G. Fort, MD²
1INDAPharma, LLC, Chapel HILL, NC
2Pozen, Inc., Chapel Hill, NC

PDF file

28

Application of a mechanism-based, population pharmacodynamic model on the time-course of platelet aggregation when naproxen and aspirin are administered alone and in combination

Lance Wollenberg, PhD¹, Varsha Iyer, PhD¹, Matt Robson, BS², Mike Gengo, BS², Francis M. Gengo, PharmD², Michelle Rainka, PharmD², Alan Forrest, PharmD¹ and Don Mager, PharmD/PhD¹
1University at Buffalo School of Pharmacy, Buffalo, NY
2Dent Neurologic Institute, Amherst, NY

PDF file

29

Development of a pharmacokinetic population model for atazanavir on a drug user population

Benjamin Guiastrennec, Pharm.D., Alan Forrest, Pharm.D., Qing Ma, Ph.D. and Gene Morse, Pharm.D.
University at Buffalo, Buffalo, NY

PDF file

30

Therapeutic drug monitoring in interstitial fluid: a feasibility study using a comprehensive panel of drugs

Tony KL Kiang, PhD¹, Veronika Schmitt, BSc¹, Urs O. Häfeli, PhD¹, Beverly Chua, DVM² and Mary HH Ensom, PharmD, FASHP, FCCP, FCSHP, FCAHS³
1Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada
2Animal Care Centre, The University of British Columbia, Vancouver, BC, Canada
3The University of British Columbia, Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada

PDF file